MTOR and hepatocellular carcinoma: Indeed, clinical trials suggest that mTOR inhibition by everolimus alone has only moderate antitumor efficacy in patients with HCC [33, 34], which may be due to feedback activation of AKT after mTOR inhibition [35, 36].